

NCT02946892 Raw comparison:

Summary:
CHIA has 24 criteria while your personal folder has 26 criteria
Total found criteria: 24/24
Total not Found: 0/24
Total Extra: 2
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Informed consent of parent(s) or legal guardian    │ Informed consent of parent(s) or legal guardian    │
│ informed consent or assent of subject as           │ informed consent or assent of subject as           │
│ applicable                                         │ applicable                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Male or female children between the ages of 10 and │ Male or female children between the ages of 10 and │
│ 35 years with congenital heart disease that has    │ 35 years with congenital heart disease that has    │
│ been palliated with a Fontan circulation           │ been palliated with a Fontan circulation           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ability of perform a maximal exercise test as      │ Ability of perform a maximal exercise test as      │
│ defined by a respiratory exchange ratio (RER)      │ defined by a respiratory exchange ratio (RER)      │
│ greater than 1 0 at the time of maximal exercise   │ greater than 1 0 at the time of maximal exercise   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The use of beta blockers within 2 months of        │ The use of beta blockers within 2 months of        │
│ randomization                                      │ randomization                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients actively listed for transplantation at    │ Patients actively listed for transplantation at    │
│ time of entry into the study or anticipated to     │ time of entry into the study or anticipated to     │
│ undergo heart transplantation interventional       │ undergo heart transplantation interventional       │
│ catheterization or corrective cardiac surgery      │ catheterization or corrective cardiac surgery      │
│ during the 7 months following entry into the study │ during the 7 months following entry into the study │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Sustained or symptomatic ventricular dysrhythmias  │ Sustained or symptomatic ventricular dysrhythmias  │
│ uncontrolled by drug therapy or the use of an      │ uncontrolled by drug therapy or the use of an      │
│ implantable defibrillator and/or significant       │ implantable defibrillator and/or significant       │
│ cardiac conduction defects e g 2nd degree or 3rd   │ cardiac conduction defects e g 2nd degree or 3rd   │
│ degree AV block or sick sinus syndrome unless a    │ degree AV block or sick sinus syndrome unless a    │
│ functioning pacemaker is in place                  │ functioning pacemaker is in place                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Uncorrected obstructive or severe regurgitant      │ Uncorrected obstructive or severe regurgitant      │
│ valve disease nondilated cardiomyopathy or         │ valve disease nondilated cardiomyopathy or         │
│ significant systemic ventricular outflow           │ significant systemic ventricular outflow           │
│ obstruction                                        │ obstruction                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known renovascular hypertension or evidence of     │ Known renovascular hypertension or evidence of     │
│ pulmonary hypertension (pulmonary vascular         │ pulmonary hypertension (pulmonary vascular         │
│ resistance > 6 Wood units) unresponsive to         │ resistance \> 6 Wood units) unresponsive to        │
│ vasodilator agents such as oxygen nitroprusside or │ vasodilator agents such as oxygen nitroprusside or │
│ nitric oxide                                       │ nitric oxide                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History or current clinical evidence of moderate-  │ History or current clinical evidence of moderate-  │
│ to-severe fixed obstructive pulmonary disease or   │ to-severe fixed obstructive pulmonary disease or   │
│ severe reactive airway diseases (e g asthma)       │ severe reactive airway diseases (e g asthma)       │
│ requiring hospitalization within the past 2 years  │ requiring hospitalization within the past 2 years  │
│ or patient currently using long-term inhaled       │ or patient currently using long-term inhaled       │
│ bronchodilators                                    │ bronchodilators                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Renal hepatic gastrointestinal or biliary disorder │ Renal hepatic gastrointestinal or biliary disorder │
│ that could impair absorption metabolism or         │ that could impair absorption metabolism or         │
│ excretion of orally administered medication        │ excretion of orally administered medication        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Concurrent terminal illness or other severe        │ Concurrent terminal illness or other severe        │
│ disease (e g active neoplasm) or other significant │ disease (e g active neoplasm) or other significant │
│ laboratory value(s) which in the opinion of the    │ laboratory value(s) which in the opinion of the    │
│ investigator could preclude participation or       │ investigator could preclude participation or       │
│ survival                                           │ survival                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Endocrine disorders such as primary aldosteronism  │ Endocrine disorders such as primary aldosteronism  │
│ pheochromocytoma hyper- or hypothyroidism insulin- │ pheochromocytoma hyper- or hypothyroidism insulin- │
│ dependent diabetes mellitus                        │ dependent diabetes mellitus                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Unwillingness or inability to cooperate or for the │ Unwillingness or inability to cooperate or for the │
│ parents or guardians to give consent or for the    │ parents or guardians to give consent or for the    │
│ child to give assent or any condition of           │ child to give assent or any condition of           │
│ sufficient severity to impair cooperation in the   │ sufficient severity to impair cooperation in the   │
│ study                                              │ study                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnancy or possible pregnancy at time of         │ Pregnancy or possible pregnancy at time of         │
│ randomization or female of child bearing potential │ randomization or female of child bearing potential │
│ who are lactating or sexually active and not       │ who are lactating or sexually active and not       │
│ taking adequate contraceptive precautions (e g     │ taking adequate contraceptive precautions (e g     │
│ intrauterine device or oral contraceptives for 3   │ intrauterine device or oral contraceptives for 3   │
│ months prior to entry into the study)              │ months prior to entry into the study)              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of an investigational drug within 30 days of   │ Use of an investigational drug within 30 days of   │
│ randomization or within 5 half-lives of the        │ randomization or within 5 half-lives of the        │
│ investigational drug (the longer period will       │ investigational drug (the longer period will       │
│ apply)                                             │ apply)                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of drug sensitivity or allergic reaction   │ History of drug sensitivity or allergic reaction   │
│ to alpha-blockers or beta-blockers                 │ to alpha-blockers or ß-blockers                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of any of the following medications within two │ Use of any of the following medications within two │
│ weeks of randomization MAO inhibitors Calcium      │ weeks of randomization MAO inhibitors Calcium      │
│ channel blockers alpha blockers beta blockers      │ channel blockers alpha blockers beta blockers      │
│ disopyramide flecainide encainide moricizine       │ disopyramide flecainide encainide moricizine       │
│ propafenone sotalol or beta adrenergic agonists    │ propafenone sotalol or beta adrenergic agonists    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hospital admission for protein losing enteropathy  │ Hospital admission for protein losing enteropathy  │
│ or plastic bronchitis within 3 months of           │ or plastic bronchitis within 3 months of           │
│ randomization                                      │ randomization                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active and/or chronic protein losing enteropathy   │ Active and/or chronic protein losing enteropathy   │
│ or plastic bronchitis (on inhaled medication to    │ or plastic bronchitis (on inhaled medication to    │
│ control the plastic bronchitis)                    │ control the plastic bronchitis)                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hypoalbuminemia defined as serum albumin <2 0g/dL  │ Hypoalbuminemia defined as serum albumin \<2 0g/dL │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Renal dysfunction defined as serum creatinine >2   │ Renal dysfunction defined as serum creatinine \>2  │
│ 0mg/dL                                             │ 0mg/dL                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hepatic dysfunction defined as serum AST and/or    │ Hepatic dysfunction defined as serum AST and/or    │
│ ALT> 3 times upper limit of normal (approximately  │ ALT\> 3 times upper limit of normal (approximately │
│ 120 IU/L however will vary depending on age)       │ 120 IU/L however will vary depending on age)       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Significant anemia or polycythemia defined as      │ Significant anemia or polycythemia defined as      │
│ hemoglobin >18gm/dL or hemoglobin <7gm/dL          │ hemoglobin \>18gm/dL or hemoglobin \<7gm/dL        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Severely elevated serum BNP defined as             │ Severely elevated serum BNP defined as             │
│ BNP>300pg/ml                                       │ BNP\>300pg/ml                                      │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have maximum age of 35 Years │
├───────────────────────────────────┤
│ Must have minimum age of 10 Years │
╘═══════════════════════════════════╛